Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: A multicentre study on 397 scans

British Journal of Haematology

Volumn 136, Issue 5, 2007, Pages 729-735

  Mele, Anna ^a   Offidani, Massimo ^b   Visani, Giuseppe ^a   Marconi, Monica ^c   Cambioli, Filippo ^a   Nonni, Marco ^b   Catarini, Massimo ^d   Brianzoni, Ernesto ^d   Berbellini, Alfonso ^d   Ascoli, Giorgio ^b   Brunori, Marino ^c   Agostini, Vanessa ^e   Corvatta, Laura ^b   Isidori, Alessandro ^a   Spinelli, Aureliano ^a   Gradari, Marinella ^a   Leoni, Pietro ^b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d Gen Prov Hosp   (Italy)

^e Infermi Hospital   (Italy)

Author keywords

18F fluorodeoxyglucose positron emission tomography; Multiple myeloma; Technetium99 sestamibi scintigraphy; X ray

Indexed keywords

C REACTIVE PROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BONE MARROW; BONE PAIN; CANCER DIAGNOSIS; CANCER INFILTRATION; CANCER SCINTISCANNING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; WHOLE BODY IMAGING; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME;

EID: 33846989347     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06489.x     Document Type: Article

References (42)

1. Adams, B.K., Fataar, A. & Nizami, M.A. (1996) Technetium-99m- sestamibi uptake in myeloma. Journal of Nuclear Medicine, 37, 1001-1002.
2. Ak, I., Aslan, V., Vardareli, E. & Gulbas, Z. (2003) Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells. Annals of Hematology, 82, 88-92.
3. Alexandrakis, M.G., Kyriakou, D.S., Passam, F., Koukouraki, S. & Karkavitsas, N. (2001) Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Annals of Hematology, 80, 349-353.
4. Alexandrakis, M.G., Kyriakou, D.S., Passam, F.H., Malliaraki, N., Christophoridou, A.V. & Karkavitsas, N. (2002) Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma. Clinical and Laboratory Haematology, 24, 155-159.
5. Alexandrakis, M.G., Kyriakou, D.S., Passam, F.H., Malliaraki, N., Vlachonikolis, I.G. & Karkavitsas, N. (2003) Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity. Hematological Oncology, 21, 17-24.
6. Alonso, O., Martinez, M., Mut, F., Delgado, L., Lago, G., De Boni, D., Bazzaro, C., Nunez, M., Garces, M., Muse, I.M., Roca, R., Touya, E., Espasandin, J. & Priario, J. (1998) Detection of recurrent malignant melanoma with 99mTc-MIBI scintigraphy. Melanoma Research, 4, 355-360.
7. Alper, E., Gurel, M., Evrensel, T., Ozkocaman, V., Akbunar, T. & Demiray, M. (2003) 99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy. Nuclear Medicine Communications, 24, 537-542.
8. Armitage, P. & Berry, G. (1994) Statistical inference. In: Statistical Methods in Medical Research, 3rd edn, pp. 93-153. Blackwell Science, Oxford.
9. Athanasoulis, T., Koutsikos, J., Moulopoulos, L.A., Tsiouris, S., Dimopoulos, M.A. & Zerva, C. (2003) Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy. Clinical Nuclear Medicine, 28, 631-635.
10. Balleari, E., Villa, G., Garre, S., Ghirlanda, P., Agnese, G., Carletto, M., Clavio, M., Ferrando, F., Gobbi, M., Mariani, G. & Ghio, R. (2001) Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica, 86, 78-84.
11. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
12. Blocklet, D., Schoutens, A., Kentos, A. & Feremans, W. (2001) Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. European Journal of Nuclear Medicine, 28, 1430-1432.
13. Bredella, M.A., Steinbach, L., Caputo, G., Segall, G. & Hawkins, R. (2005) Value of FDG PET in the assessment of patients with multiple myeloma. American Journal of Roentgenology, 184, 1199-1204.
14. Breyer, III, R.J., Mulligan, M.E., Smith, S.E., Line, B.R. & Badros, A.Z. (2006) Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiology, 35, 632-640.
15. Catalano, L., Pace, L., Califano, C., Pinto, A.M., De Renzo, A., Di Gennaro, F., Del Vecchio, S., Fonti, R., Salvatore, M. & Rotoli, B. (1999) Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica, 84, 119-124.
16. Di Gennaro, F., Catalano, L., Pace, L., de Renzo, A., Pinto, A.M., del Vecchio, S., Rotoli, B. & Salvatore, M. (1999) Tc-99m sestamibi scintigraphy in multiple myeloma. Clinical Nuclear Medicine, 24, 115-116.
17. Durie, B.G.M. & Salmon, S.E (1975) A clinical staging system for multiple myeloma. Cancer, 36, 842-854.
18. Durie, B.G.M., Waxman, A.D., D'Agnolo, A. & Williams, C.M. (1999) Whole body Tc-99m-MIBI scanning in the serial evaluation of multiple myeloma: comparison with other techniques including whole body FDG. Journal of Nuclear Medicine, 40, 215.
19. Durie, B.G., Waxman, A.D., D'Agnolo, A. & Williams, C.M. (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. Journal of Nuclear Medicine, 43, 1457-1463.
20. el-Shirbiny, A.M., Yeung, H., Imbriaco, M., Michaeli, J., Macapinlac, H. & Larson, S.M. (1997) Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. Journal of Nuclear Medicine, 38, 1208-1210.
21. Fisher, C., Vehec, A., Kashlan, B., Longa, G., Houpt, L., Howe, K., Stark, L. & Cavanaugh, D. (2000) Incidental detection of skeletal uptake on sestamibi cardiac images in a patient with previously undiagnosed multiple myeloma. Clinical Nuclear Medicine, 25, 213-214.
22. Fogelman, I., Cook, G., Israel, O. & Van der Wall, H. (2005) Positron emission tomography and bone metastases. Seminars in Nuclear Medicine, 35, 135-142.
23. Fonti, R., Del Vecchio, S., Zannetti, A., De Renzo, A., Di Gennaro, F., Catalano, L., Califano, C., Pace, L., Rotoli, B. & Salvatore, M. (2001) Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. European Journal of Nuclear Medicine, 28, 214-220.
24. Fonti, R., Del Vecchio, S., Zannetti, A., De Renzo, A., Catalano, L., Pace, L., Rotoli, B. & Salvatore, M. (2004) Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma. Cancer Biotherapy & Radiopharmaceuticals, 19, 165-170.
25. Greipp, P.R. (1992) Advances in the diagnosis and management of myeloma. Seminars in Haematology, 29, 24-45.
26. Hung, G.U., Tsai, C.C., Tsai, S.C. & Lin, W.Y. (2005) Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Research, 25, 4737-4741.
27. Jadvar, H. & Conti, P.S. (2002) Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiology, 31, 690-694.
28. Maurea, S., Acampa, W., Varrella, P., De Rosa, V., Fimiani, P., Abate, G. & Salvatore, M. (1998) Tc-99m sestamibi imaging in the diagnostic assessment of patients with lymphomas: comparison with clinical and radiological evaluation. Clinical Nuclear Medicine, 23, 283-290.
29. McCullagh, P. & Nelder, J.A. (1989) Binary data. In: Generalized Linear Models, 2nd edn (ed. by D.R. Cox, D.V. Hinkley, D. Rubin & B.W. Silverman), pp. 98-148. Chapman and Hall, London.
30. Mileshkin, L., Blum, R., Seymour, J.F., Patrikeos, A., Hicks, R.J. & Prince, H.M. (2004) A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. European Journal of Haematology, 72, 32-37.
31. Nanni, C., Zamagni, E., Farsad, M., Castellucci, P., Tosi, P., Cangini, D., Salizzoni, E., Canini, R., Cavo, M. & Fanti, S. (2006) Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 33, 525-531.
32. Orchard, K., Barrington, S., Buscombe, J., Hilson, A., Prentice, H.G. & Mehta, A. (2002) Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. British Journal of Haematology, 117, 133-135.
33. Pace, L., Catalano, L., Pinto, A., De Renzo, A., Di Gennaro, F., Califano, C., Del Vecchio, S., Rotoli, B. & Salvatore, M. (1998) Different patterns of technetium-99m sestamibi uptake in multiple myeloma. European Journal of Nuclear Medicine, 25, 714-720.
34. Pace, L., Catalano, L., Del Vecchio, S., Di Gennaro, F., De Renzo, A., Sica, G., Califano, C., Tedesco, N., Borrelli, G., Rotoli, B. & Salvatore, M. (2001) Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up. European Journal of Nuclear Medicine, 28, 304-312.
35. Pace, L., Catalano, L., Del Vecchio, S., De Renzo, A., Fonti, R., Salvatore, B., Andretta, C., Di Nuzzo, C., Rotoli, B. & Salvatore, M. (2005a) Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 49, 281-285.
36. Pace, L., Del Vecchio, S. & Salvatore, M. (2005b) Technetium 99m sestamibi in multiple myeloma. Radiology, 234, 312-313.
37. Pace, L., Salvatore, M. & Del Vecchio, S. (2006) Use of 99mTc-sestamibi scintigraphy in multiple myeloma. Journal of Nuclear Medicine, 47, 555.
38. Schirrmeister, H., Buck, A.K., Bergmann, L., Reske, S.N. & Bommer, M. (2003) Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biotherapy and Radiopharmaceuticals, 18, 841-845.
39. Svaldi, M., Tappa, C., Gebert, U., Bettini, D., Fabris, P., Franzelin, F., Osele, L. & Mitterer, M. (2001) Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Annals of Hematology, 80, 393-397.
40. Tirovola, E.B., Biassoni, L., Britton, K.E., Kaleva, N., Kouykin, V. & Malpas, J.S. (1996) The use of 99mTc-MIBI scanning in multiple myeloma. British Journal of Cancer, 74, 1815-1820.
41. Wakasugi, S., Teshima, H., Nakamura, H., Hashizume, T., Maeda, T., Hiraoka, A., Hasegawa, Y. & Masaoka, T. (1998) Tc-99m MIBI localization in bone marrow: a marker of bone marrow malignancy. Clinical Nuclear Medicine, 23, 664-671.
42. Wakasugi, S., Noguti, A., Katuda, T., Hashizume, T. & Hasegawa, Y. (2002) Potential of (99m)Tc-MIBI for detecting bone marrow metastases. Journal of Nuclear Medicine, 43, 596-602.